Sales of Lucentis ranibizumab have grown to $2.9 billion in 2010 since the drug was approved for age-related macular degeneration in the U.S. in June 2006 and the EU in January 2007. Year-over-year sales growth has started to slow, with total 2010 sales up 20% vs. a 35% increase in 2009 and a 46% increase in 2008.

For 1Q11, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported U.S. sales of CHF392 million ($428 million), up 35% from 1Q10 in constant currencies. Novartis AG (NYSE:NVS; SIX:NOVN) reported ex-U.S. sales of $444 million, up 18% in constant currencies. (A) Lucentis was approved in Switzerland and India in 2006; $B; Source: Genentech, Roche, Novartis earnings statements